Abstract: The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).

Abstract: Compositions, methods, and kits that deliver a compound, such as 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole, through a keratin substrate are presented.

Abstract: A method to improve gastrointestinal health by colonic microbiome alteration, the method comprising administering to a subject in need thereof an effective amount of a composition comprising one or more indigestible oligosaccharides and less than about 20% digestible saccharides by weight, wherein an abundance of one or more beneficial bacteria in the subject's colonic micro-biome is increased after administration of the composition.

Abstract: Water-soluble, cell-permeable nanomicelles containing ceramides and a steviol glycoside, such as rubusoside, are disclosed. The ceramide-steviol glycoside complex has high water solubility, and can be used for treating cancers with p53 mutations. Preliminary results have shown that the Cer nanomicelles are effective in restoring p53 protein expression, and that they are functionally dominant over p53 mutants. The novel nanomicelles restore a wild-type phenotype, and have very low toxicity to noncancerous cells. The novel Cer nanomicelles may be used in treating p53-associated cancers.

Abstract: A method for treating a human subject having congestive heart failure is disclosed herein. An exemplary method includes orally administering a 10 g to 50 g dose of D-ribose daily to a subject having congestive heart failure, wherein the D-ribose is administered in a single dose after fasting, and the administration of D-ribose is continued over a period of time effective to improve cardiac and/or physical function of the subject.

Abstract: Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and/or impaired mood.

Abstract: Disclosed are methods of treating fibrosis in a patient in need thereof that includes administering to the patient an amount of an active agent, as identified herein, that is therapeutically effective to inhibit myofibroblast formation and thereby treat the fibrosis. Also disclosed is a recombinant cell line that includes a recombinant gene that expresses a detectable expression product in a dose-dependent response to TGF?, as well as methods of identifying a compound that inhibits TGF?-mediated expression of the detectable expression product.

Abstract: Disclosed are methods and preparations useful for reducing fat at a targeted area(s) on a human. The preparations comprise as an active ingredient an adipolysis enhancing (i.e., fat-melting) amount of an active ingredient, paeoniflorin (PF). The preparations may be provided as an injectable preparation or as a topically applied preparation, such as in the form of a crème or lotion. In topical preparations, the active ingredient paeoniflorin may be contained within nanospheres, such as albumin nanospheres. The PF-containing preparations may also include a permeant, such as azone. The method may be accompanied by the application of ultrasound to the area being treated prior to, during or after, or prior to, during, and after application of the paeoniflorin preparation to an area of the body in which fat reduction is desired.

Abstract: A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions.

Abstract: The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.

Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.

Abstract: This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.

Abstract: HAT-Pi chemotherapy arrests uncontrolled replication and metastatic migration of neoplastic cells by inhibiting enzymatic activity of poly (ADP-ribose) polymerase 1 (PARP 1) through administration of one or more halogenated analogs of thymidine (HAT). A full HAT-Pi treatment regimen, involving repeated HAT-Pi courses over extended periods (24 weeks), may lead to tumor regression through HAT-Pi-induced neoplastic cell death and disintegration. Pain related to neoplastic disease may be reduced during HAT-Pi treatment and for extended periods thereafter. Myelosuppression is a potentially life-threatening but manageable HAT-Pi toxicity and other HAT-Pi side-effects may be tolerated by most patients. Acquired patient resistance to HAT-Pi has not been observed. HAT-Pi is potentially teratogenic and is restricted to post-reproductive adults with advanced neoplastic disease. Modified HAT-Pi treatment regimens may allow for broader application to treat additional individuals and/or conditions.

Abstract: In order to provide a novel cancer treatment method using a FTD-TPI combination drug that exhibits markedly excellent anti-tumor effects with fewer side effects, the present invention provides an anti-tumor agent characterized in that the FTD-TPI combination drug and an anti-tumor platinum complex are administered in combination.

Abstract: We disclose nucleoside derivatives useful as drugs, particularly for the treatment of chronic lymphocytic leukemia.

Abstract: The present disclosure relates to a method which allows direct formation of gel-like solutions of polyglucosamine at neutral pH?7 to 8, eliminating the need of prior dissolution of polyglucosamine in acidic environment; and to a homogeneous liquid combination of polyglucosamine-glyoxylate with hyaluronan.

Abstract: Provided is a pharmaceutical composition for the treatment of disorders such as Niemann-Pick disease and GM1 gangliosidosis which are caused by the storage of cholesterol, such as lysosomal storage disease. Also provided is a method for screening for said pharmaceutical compositions that uses iPS cell strains that phenocopy phentotypes of these disorders. Provided is a pharmaceutical composition for the treatment and/or prevention of lysosomal storage disease, characterized by containing hydroxypropyl-?-cyclodextrin as an active ingredient. Also provided are an iPS cell strain derived from patients suffering from intractable disorders and prepared using a new temperature-sensitive Sendai virus vector, and a screening method for pharmaceuticals using said iPS cell strain.

Abstract: There is described an ulvan containing composition. This composition is a viscosupplement composition and can be used in the treatment or prophylaxis of arthritis. Also described is a method of treating a musculoskeletal disease, such as 5 arthritis, by administering the ulvan containing composition.

Abstract: The present invention relates to pharmaceutical formulations containing a combination of specific high-molecular weight hyaluronic acid derivatives and chondroitin sulfate to be used in the treatment of osteoarthritis, of subchondral damage, osteoporosis, synovitis, tenosynovitis, tendinitis, tendinosis, as an intra-articular washing liquid and as a viscous substitute of synovial fluid following osteochondral surgery. These formulations are also suitable for the treatment of interstitial cystitis.

Abstract: Disclosed herein are compositions and methods for preventing or treating acute or chronic oral mucositis, esophagitis, enteritis, colitis, or gastrointestinal acute radiation syndrome (GI-ARS) caused by radiation exposure, using one or more enteron sorbent polymers administered gastrointestinally (e.g. orally, via feeding or gastric tube, via ostomy, or rectally).

Abstract: One aspect of the present invention relates generally to injectable compositions. In one embodiment, the compositions include 2-hydroxyethyl methacrylate and a dimethacrylate crosslinker. Another aspect of the invention relates generally to methods of using such compositions for thermal ablation and for the occlusion of body vessels.

Abstract: The subject of the invention is an N-sulfonic polyallylamine derivative (NSPAH) with Formula 1, wherein R is —SO3? or —H, and n is an integer from 150 to 15000; an application of the N-sulfonic polyallylamine derivative as a medicine, particularly for prevention and treatment of respiratory tract infections caused by the human metapneumovirus (hMPV), respiratory tract infections caused by the human rhinoviruses (HRV), and infections caused by the influenza A virus; as well as a pharmaceutical composition comprising the N-sulfonic polyallylamine derivative and application thereof.

Abstract: Provided herein are metal nanoclusters, having a high absorption to volume ratio, and uses of the same, such as in generating singlet oxygen, or in protecting surfaces from high intensity light.

Abstract: The present invention provides stabilized amorphous calcium carbonate (ACC) formulations, comprising ACC and a non-aqueous liquid carrier in which the ACC is dispersed. The present invention further provides cosmetic and pharmaceutical compositions comprising ACC.

Abstract: The present invention is directed to methods and compositions for the treatment or prevention of actinic keratosis and/ or for countering the effects of skin aging and/ or damage to blood vessels and fine wrinkling. The present invention provides for a composition comprising aluminum fluoride or chemical compounds which releases aluminum fluoride to be used to treat or reduce the negative effects of actinic keratosis or sun-induced skin aging and associated conditions, for example, damaged blood vessels and fine wrinkling.

Abstract: A composition of stabilized chlorine dioxide at a concentration range of about 0.0004% to about 0.8% (w/v) having anti fungal properties to prevent oral fungal infections and method of use are disclosed.

Abstract: Redox signaling gels are disclosed. Such gels include a composition with at least one reactive oxygen species (ROS) and a rheology modifier. Also presented herein is a process for making the gels which includes making the composition by taking the steps of purifying water to produce ultra-pure water, combining a salt to the ultra-pure water to create a salinated water, electrolyzing the salinated water at a temperature of 4.3 to 5.8° C. such that the electrolyzing is accomplished with an anode, cathode and power source such that the power source comprises a transformer and a rectifier and does not comprise a filter capacitor.

Abstract: A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject's immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.

Abstract: Disclosed are compositions, methods of use, and pharmaceutical preparations useful for treatment of cancer. In one embodiment dendritic cells (DC) are generated from a patient in need of treatment, matured utilizing a leukocyte lysate, and readministered into the same patient without the use of antigen pulsing. DC from different tissues, different stages of maturation, and different methods of inducing DC maturation are disclosed.

Abstract: It has been discovered that the inhibition of PI3K-?, but not PI3K-? or PI3K-?, delays the terminal differentiation of CD8 T cell and maintains the TCM phenotype thus enhancing their proliferative ability and survival while maintaining their cytokine and Granzyme B production ability. Methods and compositions for delaying or inhibiting terminal differentiation of CD8 T cells are provided.

Abstract: A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.

Abstract: The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting.

Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus, including cells that lack expression of one or more classic HLA genes but are not targeted by Natural Killer (NK) cells for lysis.

Abstract: Determining and implementing individualized platelet support regimens (e.g., administering specified platelet numbers; and, schedules for administration or other intervention, in accordance with the requirements assessed for individual patients) by: monitoring platelet clearance kinetics; analyzing the kinetics to determine value(s) proportionally representing both the extent and frequency of vascular injury, and using such value(s) to determine the momentary requirement for maintaining vascular integrity, and constructing a corresponding platelet administration regimen where said regimen preferably provides for the utilization of platelets selected, from a platelet inventory, in accordance with the recipient's molecular “type”. Releasing from an inventory of a platelet inventory system the particular typed or profiled platelet amounts required to satisfy the platelet administration regimen of each patient.

Abstract: The disclosure relates to methods and compositions for improving homing of cells including mesenchymal stem cells (MSCs). Compositions include compounds described herein as capable of inducing expression by MSCs of cell surface homing ligand molecules such as CD1 la, promoting increased firm adhesion by MSCs in an in vitro shear flow assay, increasing binding to an adhesion molecule such as E-selectin or ICAM-1, and/or demonstrating anti-inflammatory activity upon in vivo systemic administration in cell therapy using human MSCs. Also described are screening methods to identify small molecule compounds for improving a homing function of MSCs.

Abstract: Provided herein are methods of treating EIPH in a subject in need thereof. The methods comprise administering an effective amount of a pharmaceutical composition to the subject. In some embodiments, the pharmaceutical composition comprises a granuloma fluid, or a composition derived from a granuloma fluid. In some embodiments, the pharmaceutical composition comprises a cell. These pharmaceutical compositions may be administered by any suitable route of administration, and may be administered with one or more further therapeutic agents. Also provided are kits comprising pharmaceutical compositions for use with the methods provided herein.

Abstract: The present invention provides a method of inhibiting progression of or preventing renal disorder, the method comprising applying a cell sheet composition for inhibiting progression of or preventing renal disorder to at least one part of the surface of a kidney, wherein the part of the surface is uncovered by a fibrous capsule of the kidney. The present invention also provides a cell sheet composition for inhibiting progression of or preventing renal disorder, the cell sheet composition comprising a cell that has a function of producing a hepatocyte growth factor (HGF). The present invention also provides a method of producing a cell sheet composition for inhibiting progression of or preventing renal disorder.

Abstract: The presently disclosed subject matter provides compositions, methods, and kits for transfecting adipose-derived mesenchymal stem cells (AMSCs) in freshly extracted adipose tissue using nanoparticles comprising biodegradable polymers self-assembled with nucleic acid molecules. The presently disclosed subject matter also provides methods for treating a neurological disease in a patient in need thereof, the method comprising administering the AMSCs transfected with the nucleic acid molecules to the patient, wherein the nucleic acid molecules encode one or more bioactive molecules functional in the treatment of a neurological disease, particularly wherein the neurological disease is a brain tumor.

Abstract: This disclosure relates to apoptotic bodies. The disclosure particularly relates to a composition comprising the apoptotic bodies. The disclosure further relates to preparation of apoptotic bodies from stem cells. The disclosure also relates to medical treatments comprising the use of the composition comprising the apoptotic bodies. The apoptotic bodies may comprise apoptotic stem cells. The apoptosis of a cell may be induced by a starvation method, an ultra-violet irradiation method, a thermal stress method, a staurosporine method, or a combination thereof.

Abstract: Disclosed herein are reagent-cell complexes comprising one or more definitive endoderm cells. Also described herein are compositions for detecting definitive endoderm. Method of enriching, isolating and/or purifying definitive endoderm cells are also disclosed.

Abstract: The present invention relates to a conditioned medium (CM) which is obtained by culturing, in a liquid culture medium, placental mesenchymal stem cells isolated from the placental tissue of pregnant women who not affected by preeclampsia. The conditioned medium of the present invention includes at least IL-6, IL-8 and MCP-1 proteins. The conditioned medium of the present invention is effective for the therapeutic treatment of preeclampsia.

Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

Abstract: The invention relates to a pharmaceutical composition consisting of snail slime of Helix aspersa muller (Cryptophalus aspersus) (5% to 50%), chamomile extract (5% to 10%), honey (5% to 10%), and additives and/or pharmaceutically accepted excipients to form a formulation having low, intermediate or high viscosity (1 to 1000 Pa·s). By dipping a patch or bandage of gauzy fabric into the composition in the form of a lotion, shampoo, soap, cream or gel, the composition is applied on lesions caused by psoriasis. The composition can also contain natural extracts, such as marigold extract, propolis, and vegetable oils. The invention also claims a method for obtaining the composition and the use thereof to prepare a drug or device for preventing, treating or curing psoriasis lesions on the head, the skin of the body or of the face.

Abstract: The invention provides compositions based on either medicinal honey containing broad spectrum antibacterial activities of peroxide, polyphenols and methylglyoxal, or an effective amount of an active anti-inflammatory ingredient of mineral solids fortified with methylglyoxal antibacterial activity, or a mixture of both for the treatment of wounds; and methods of treating a wound, comprising contacting a wound with any one of the above compositions or a wound dressing containing any one of the above compositions.

Abstract: The present disclosure provides engineered bacterial cells comprising a heterologous gene encoding a propionate catabolism enzyme. In another aspect, the engineered bacterial cells further comprise at least one heterologous gene encoding a transporter of propionate or a kill switch. The disclosure further provides pharmaceutical compositions comprising the engineered bacteria, and methods for treating disorders involving the catabolism of propionate, such as Propionic Acidemia and Methylmalonic Acidemia, using the pharmaceutical compositions.

Abstract: Methods of inhibiting or reducing tumor metabolism and growth are disclosed. A composition containing oxygen scavenging membrane fragments and anaerobe bacteria is injected into a tumor to interfere with tumor growth and metabolism, leading to tumor necrosis. The composition may also contain a cryoprotectant, which permits the composition to be stored at sub-zero temperatures without freezing.

Abstract: The present application provides microbiota-related compositions, methods, and dosing regimens for treating various microbiota-related disorders with improved cure rates by replacing or supplementing or modifying a subject's colon microbiota.

Abstract: The present invention relates to compositions comprising probiotic and prebiotic components, mineral salts, lactoferrin, and possibly saccharomycetes, which perform correct, effective colonisation of the probiotic components administered, with enteric consequences which involve maintaining and/or restoring intestinal health and preventing the consequences of common dysbioses of the digestive tract caused by stress, incorrect dietary habits and antibiotic treatments. Said compositions also have a concomitant anti-inflammatory and immunomodulating action.

Abstract: Microencapsulated probiotic bacteria protected from degradation by acidic aqueous solutions, high bile salt concentrations, elevated temperatures, and prolonged storage and having an increased anti-bacterial activity as compared to their non-microencapsulated counterparts. The microencapsulated probiotic bacteria comprise probiotic bacteria encapsulated in microcapsules. The probiotic bacteria comprise live Lactobacillus plantarum cells. Each of the microcapsules comprises a matrix of a gelled alginate. The matrix wholly envelops the probiotic bacteria within the matrix. An outer surface of the matrix has a coating consisting essentially of one vegetable oil selected from the group consisting of olive oil and canola oil, or an outer surface of the matrix is treated with sodium chloride. The microencapsulated probiotic bacteria have an average particle size of less than 1000 microns (?m) in diameter.

Abstract: The present invention aims to prevent and/or treat health-related conditions in infants born with a non-optimal intestinal microbiome, by providing specific probiotic lactic acid bacterial strains to the pregnant mother. This will enable early colonization of the infant gut, even before birth, and thus prevent and/or treat health-related conditions associated with non-optimal microbiome. Thus, the present invention provides a probiotic microorganism for use in the treatment of a fetus or neonate, wherein said probiotic microorganism is administered to the oral cavity of a pregnant female in a formulation suitable to colonize the oral cavity, wherein said probiotic microorganism is thereby administered to the fetus.